Latest news
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo has entered into a feasibility…
Iconovo Accelerator Program
On June 1st, 2023 Iconovo launched its Iconovo Accelerator to facilitate the opportunities for the company’s customers to obtain EU funding for the development…
Press releases
Jan 13, 2026, 13:40
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Jan 13, 2026, 13:40
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se